Aurigene Oncology Limited, a subsidiary of Dr. Reddy’s Laboratories, has received an order from the GST Appellate Authority regarding a tax demand, including a penalty. The penalty amounts to ₹64,94,862. The order, received on November 25, 2025, relates to a dispute over tax liability. The company is evaluating its options for filing an appeal.
GST Penalty Imposed
Aurigene Oncology Limited has received an order from the GST Appellate Authority, leading to a penalty of ₹64,94,862. This matter pertains to a disagreement concerning tax obligations, as detailed in the official communication received by the company on November 25, 2025.
Details of the Order
The order stems from an appeal filed by Aurigene Oncology, which was subsequently dismissed on May 24, 2024. The appeal sought to challenge a demand, including a penalty levied under the relevant GST Acts from 2017. The core issue involves the authority’s claim that Aurigene incorrectly declared its tax liability when filing its annual GSTR-09 returns. The official notification of the order was delivered to the company via email.
Company’s Response
Dr. Reddy’s Laboratories is currently assessing the situation and determining the next steps, which includes evaluating the possibility of filing a further appeal with the appropriate appellate authority. According to their internal evaluation, the company believes that this penalty will not have a material impact on its financials, operations, or other activities.
Source: BSE
